Why the study?
Does big endothelin-1 predict major adverse cardiovascular events in myocardial infarction patients younger than 35 years old?
Does big endothelin-1 predict major adverse cardiovascular events in myocardial infarction patients younger than 35 years old?
Big ET-1 is an independent predictor for major adverse cardiovascular events in young patients (<35 years) with myocardial infarction.
Should not yet inform risk stratification in young MI; leaves open Big ET-1's incremental value in prospective cohorts.
AIM: The predictive value of big endothelin-1 (ET-1) for cardiovascular outcomes in myocardial infarction (MI) patients younger than 35 years old has not been characterized. METHODS: A total of 565 consecutive MI patients younger than 35 years old were studied and followed up for 37.78 ± 24.9 months. RESULTS: Multivariable Cox regression analysis showed that big ET-1 was positively correlated with major adverse cardiovascular events [MACEs] (odds ratio: 3; 95% CI: 1.92-4.68; p < 0.001). The area under receiver operating characteristics curve showing the predictive value of big ET-1 on MACEs was 0.67. CONCLUSION: The study first demonstrated that big ET-1 was an independent predictor for MACEs in MI patients younger than 35 years old.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: